> ## Content Index
> Fetch the complete content index at: https://www.fdaweb.com/llms.txt
> Use this file to discover other available public pages before exploring further.

# Improvements Suggested for Non-Opioid Analgesic Guidance
- URL: https://www.fdaweb.com/improvements-suggested-for-non-opioid-analgesic-guidance/
- Published: 2022-04-12T12:00:00.000Z
- Updated: 2026-09-14T17:40:11.000Z
- Author: David McFarland
- Tags: Drugs, #legacy-id-D5151578

The Biotechnology Innovation Organization says there are several ways FDA could improve its draft guidance on developing non-opioid analgesics for acute pain. Its [recommendations](https://www.regulations.gov/comment/FDA-2021-N-0556-0020?ref=fdaweb.com) cover considerations for a general acute pain indication, novel mechanism of action, use of FDA expedited programs, FDA-sponsor engagement, chronic pain guidance development, and future considerations and next steps.

GlaxoSmithKline submitted line-by-line technical [comments](https://www.regulations.gov/comment/FDA-2021-N-0556-0017?ref=fdaweb.com).